0000912057-01-534441.txt : 20011010
0000912057-01-534441.hdr.sgml : 20011010
ACCESSION NUMBER: 0000912057-01-534441
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20011004
ITEM INFORMATION: Other events
FILED AS OF DATE: 20011004
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENOME THERAPEUTICS CORP
CENTRAL INDEX KEY: 0000356830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 042297484
STATE OF INCORPORATION: MA
FISCAL YEAR END: 0831
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-10824
FILM NUMBER: 1752123
BUSINESS ADDRESS:
STREET 1: 1OO BEAVER ST
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7813982300
MAIL ADDRESS:
STREET 1: 100 BEAVER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC
DATE OF NAME CHANGE: 19920703
8-K
1
a2060547z8-k.txt
8-K
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): October 4, 2001
--------------------
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-10824 04-2297484
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification Number)
100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453
(Address, of principal executive offices, including zip code)
(781) 398-2300
(Registrant's Telephone number including area code)
--------------------
--------------------------------------------------------------------------------
PAGE 1 OF 3 PAGES.
Item 5. OTHER EVENTS
Due to current market conditions, Genome Therapeutics Corp. has decided
to discontinue its offer and sale of up to 1,950,000 shares of common stock (the
"Shares") as described in the prospectus supplement dated June 28, 2001, filed
with the Securities and Exchange Commission pursuant to Rule 424(b)(5) of the
Securities Act of 1933, as amended. The Company intends to continue to evaluate
market conditions and may seek to sell the Shares through underwriters, dealers
or agents or directly to one or more purchasers.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By /s/ Stephen Cohen
---------------------
Name: Stephen Cohen
Title: Chief Financial Officer
Date: October 4, 2001
-3-